Recursion Pharmaceuticals (RXRX) Enterprise Value (2020 - 2026)
Recursion Pharmaceuticals' (RXRX) quarterly Enterprise Value came in at -$660.0 million in Q1 2026, down 31.07% YoY from -$957.5 million in Q1 2025, and up 11.75% on a QoQ basis from -$747.9 million in Q4 2025.
Recursion Pharmaceuticals (RXRX) Enterprise Value (2020 - 2026) Analysis & Trends
Recursion Pharmaceuticals (RXRX) has 7 years of Enterprise Value data on file, last reported at -$660.0 million in Q1 2026.
- Quarterly Enterprise Value fell 31.07% year-over-year to -$660.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$660.0 million (down 31.07% YoY) and the FY2025 annual result came in at -$747.9 million, down 25.19% from the prior year.
- Enterprise Value improved to -$660.0 million in Q1 2026, from -$747.9 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$299.5 million in Q1 2024 to a low of -$747.9 million in Q4 2025.
- A 5-year average of -$502.7 million and a median of -$476.1 million in 2024 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2022 — Enterprise Value plunged 132.47% — and 2024, when it surged 36.87%.
- Tracing RXRX's Enterprise Value over 5 years: stood at -$551.2 million in 2022, then rose by 28.37% to -$394.8 million in 2023, then slumped by 51.32% to -$597.4 million in 2024, then dropped by 25.19% to -$747.9 million in 2025, then increased by 11.75% to -$660.0 million in 2026.
- The last three Enterprise Value figures came in at -$660.0 million (Q1 2026), -$747.9 million (Q4 2025), and -$663.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Recursion Pharmaceuticals | 1.69 Bn | 1.14 Bn | -3.82 Mn | -551.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -551.07 Mn |
| Mar 31, 2026 | -659.98 Mn |
| Dec 31, 2025 | -747.89 Mn |
| Sep 30, 2025 | -662.97 Mn |
| Jun 30, 2025 | -528.22 Mn |
| Mar 31, 2025 | -503.53 Mn |
| Dec 31, 2024 | -597.40 Mn |
| Sep 30, 2024 | -429.20 Mn |
| Jun 30, 2024 | -476.12 Mn |
| Mar 31, 2024 | -299.52 Mn |
| Dec 31, 2023 | -394.80 Mn |
| Sep 30, 2023 | -389.58 Mn |
| Jun 30, 2023 | -409.20 Mn |
| Mar 31, 2023 | -474.46 Mn |
| Dec 31, 2022 | -551.19 Mn |
| Sep 30, 2022 | -456.74 Mn |
| Jun 30, 2022 | -455.78 Mn |
| Mar 31, 2022 | -509.41 Mn |
| Dec 31, 2021 | -516.56 Mn |
| Sep 30, 2021 | -578.91 Mn |